Strategies for developing human osteocalcin standards: A critical evaluation

Scandinavian Journal of Clinical and Laboratory Investigation, Supplement

Volumn 57, Issue 227, 1997, Pages 100-104

  Houben, Roger ^a   Soute, Berry A M ^a   Knapen, Marjo H J ^a   Vermeer, Cees ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Bone formation; Bone marker; Vitamin K; Carboxyglutamate

Indexed keywords

ASCORBIC ACID; BIOCHEMICAL MARKER; OSTEOCALCIN; BIOLOGICAL MARKER;

ADULT; AGED; BONE DENSITY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DETERMINATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; OSTEOPOROSIS; PRIORITY JOURNAL; STANDARD; TECHNIQUE; AMINO ACID SEQUENCE; BLOOD; CHEMISTRY; EVALUATION; MOLECULAR GENETICS; REVIEW;

AMINO ACID SEQUENCE; BIOLOGICAL MARKERS; EVALUATION STUDIES; HUMANS; MOLECULAR SEQUENCE DATA; OSTEOCALCIN; REFERENCE STANDARDS;

EID: 0030624665     PISSN: 0085591X     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365519709168315     Document Type: Conference Paper

References (24)

1. Hauschka PV, Lian JB, Cole DEC, Gundberg CM. Osteocalcin and matrix Gla protein: vitamin K dependent proteins in bone. Phys Rev 1989; 69: 990-1047.
2. Price PA. Role of vitamin K-dependent proteins in bone metabolism. Annu Rev Nutr 1988; 8: 565-83.
3. Vermeer C. Gamma-carboxyglutamate-containing proteins and the vitamin K-dependent carboxylase. Biochem J 1990; 266: 625-36.
4. Furie B, Furie BC. Molecular basis of vitamin K-dependent γ-carboxylation. Blood 1990; 75: 1753-62.
5. Brown JP, Delmas PD, Malaval L, Edouard C, Chapuy MC, Meunier PJ. Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet 1984; i: 1091-3.
6. Ismail F, Epstein S, Pacific R, Droke D, Thomas SB, Avioli LV. Serum bone Gla protein (BGP) and other markers of bone mineral metabolism in postmenopausal osteoporosis. Calcif Tissue Int 1986; 39: 230-3.
7. Price PA, Parthemore JG, Deftos LJ, Nishimoto SK. New biochemical marker for bone metabolism. Measurement by radioimmunoassay of bone Gla protein in the plasma of normal subjects and patients with bone disease. J Clin Invest 1980; 66: 878-83.
8. Power MJ, Fottrell PF. Osteocalcin: diagnostic methods and clinical applications. Crit Rev Clin Lab Sci 1991; 28: 287-335.
9. Díaz Diego EM, Guerrero R, de la Piedra C. Six osteocalcin assays compared. Clin Chem 1994; 40: 2071-7.
10. Knapen MHJ, Eisenwiener H-G, Vermeer C. Osteocalcin detection in aging serum and whole blood: stability of different osteocalcin fractions. Clin Chim Acta, in press.
11. 1 levels in fractured neck of femur. Lancet 1984; ii: 283.
12. Hart JP, Shearer MJ, Klenerman L, Caterall A, Reeve J, Sambrook PN, Dodds RA, Bitensky L, Chayen J. Electrochemical detection of depressed circulating levels of vitamin K1 in osteoporosis. J Clin Endocrinol Metab 1985; 60: 1268-9.
13. Bitensky L, Hart JP, Caterall A, Hodges SJ, Pilkington MJ, Chayen J. Circulating vitamin K levels in patients with fractures. J Bone Joint Surg 1988; 70-B: 663-4.
14. Hodges SJ, Akesson K, Vergnaud P, Obrant K, Delmas PD. Circulating levels of vitamins K1 and K2 decreased in elderly women with hip fracture. J Bone Miner Res 1993; 8: 1241-5.
15. Jie K-SG, Bots ML, Vermeer C, Witteman JCM, Grobbee DE. Vitamin K status and bone mass in women with and without aortic atherosclerosis: a population-based study. Calcif Tissue Int 1996; 59: 352-6.
16. Knapen MHJ, Hamulyák K, Vermeer C. The effect of vitamin K supplementation on circulating osteocalcin (bone Gla-protein) and urinary calcium excretion. Ann Int Med 1989; 111: 1001-5.
17. Knapen MHJ, Jie K-SG, Hamulyák K, Vermeer C. Vitamin K-induced changes in markers for osteoblast activitiy and urinary calcium loss. Calcif Tissue Int 1993; 53: 81-5.
18. Szulc P, Arlot M, Chapuy M-C, Duboeuf F, Meunier PJ, Delmas PD. Serum undercarboxylated osteocalcin correlates with hip bone mineral density in elderly women. J Bone Miner Res 1994; 9: 1591-5.
19. Szulc P, Chapuy M-C, Meunier PJ, Delmas PD. Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest 1993; 91: 1769-74.
20. Chu K, Wu S-M, Stanley T, Stafford DW, High KA. A mutation in the propeptide of factor IX leads to warfarin sensitivity by a novel mechanism. J Clin Invest 1996; 98: 1619-25.
21. Cairns JR, Price PA. Direct demonstration that the vitamin K-dependent bone Gla protein is incompletely γ-carboxylated in humans. J Bone Miner Res 1994; 9: 1989-97.
22. Nakao M, Nishiuchi Y, Nakata M, Kimura T, Sakakibara S. Synthesis of human osteocalcins: γ-carboxyglutamic acid at position 17 is essential for a calcium-dependent conformational transition. Pept Res 1994; 7: 171-4.
23. Chang GTG, Ploos van Amstel HK, Hessing M, Reitsma PH, Bertina RM, Bouma BN. Expression and characterization of recombinant human protein S in heteologous cells - Studies of the interaction of amino acid residues Leu-608 to Glu-612 with human C4b-binding protein. Thromb Haemostas 1992; 67: 526-32.
24. Christiansen WT, Castellino FJ. Properties of recombinant chimeric human protein C and activated protein C containing the γ-carboxyglutamic acid and trailing helical stack domains of protein C replaced by those of human coagulation factor IX. Biochemistry 1994; 33: 5901-11.